Anti-MYC monoclonal antibody

Pre-made anti-MYC monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to MYC/MYC products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T36121-Ab-1/ GM-Tg-hg-T36121-Ab-2Anti-Human MYC monoclonal antibodyHuman
GM-Tg-rg-T36121-Ab-1/ GM-Tg-rg-T36121-Ab-2Anti-Rat MYC monoclonal antibodyRat
GM-Tg-mg-T36121-Ab-1/ GM-Tg-mg-T36121-Ab-2Anti-Mouse MYC monoclonal antibodyMouse
GM-Tg-cynog-T36121-Ab-1/ GM-Tg-cynog-T36121-Ab-2Anti-Cynomolgus/ Rhesus macaque MYC monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T36121-Ab-1/ GM-Tg-felg-T36121-Ab-2Anti-Feline MYC monoclonal antibodyFeline
GM-Tg-cang-T36121-Ab-1/ GM-Tg-cang-T36121-Ab-2Anti-Canine MYC monoclonal antibodyCanine
GM-Tg-bovg-T36121-Ab-1/ GM-Tg-bovg-T36121-Ab-2Anti-Bovine MYC monoclonal antibodyBovine
GM-Tg-equg-T36121-Ab-1/ GM-Tg-equg-T36121-Ab-2Anti-Equine MYC monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T36121-Ab-1/ GM-Tg-hg-T36121-Ab-2; GM-Tg-rg-T36121-Ab-1/ GM-Tg-rg-T36121-Ab-2;
GM-Tg-mg-T36121-Ab-1/ GM-Tg-mg-T36121-Ab-2; GM-Tg-cynog-T36121-Ab-1/ GM-Tg-cynog-T36121-Ab-2;
GM-Tg-felg-T36121-Ab-1/ GM-Tg-felg-T36121-Ab-2; GM-Tg-cang-T36121-Ab-1/ GM-Tg-cang-T36121-Ab-2;
GM-Tg-bovg-T36121-Ab-1/ GM-Tg-bovg-T36121-Ab-2; GM-Tg-equg-T36121-Ab-1/ GM-Tg-equg-T36121-Ab-2
Products NameAnti-MYC monoclonal antibody
Formatmab
Target NameMYC
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-MYC monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T36121-Ag-1Recombinant multi-species MYC/ MRTLC/ bHLHe39 protein
    ORF Viral VectorvGMLV000287human MYC Lentivirus particle
    ORF Viral VectorvGMLV000614human MYC Lentivirus particle
    ORF Viral VectorpGMLV000614human MYC Lentivirus plasmid
    ORF Viral VectorpGMLV000288human MYC Lentivirus plasmid
    ORF Viral VectorpGMAP000557Human MYC Adenovirus plasmid
    ORF Viral VectorpGMLV000287human MYC Lentivirus plasmid
    ORF Viral VectorvGMAP000557Human MYC Adenovirus particle
    ORF Viral VectorvGMLV000288human MYC Lentivirus particle
    ORF Viral VectorpGMLV000144mouse Myc Lentivirus plasmid
    ORF Viral VectorpGMAD000083mouse Myc Adenovirus plasmid
    ORF Viral VectorpGMAD000252rat Myc Adenovirus plasmid
    ORF Viral VectorpGMAD000465Norway rat Myc Adenovirus plasmid
    ORF Viral VectorpGMAAV000056mouse Myc AAV plasmid
    ORF Viral VectorvGMLV000144mouse Myc Lentivirus particle
    ORF Viral VectorvGMAD000083mouse Myc Adenovirus particle
    ORF Viral VectorvGMAD000252rat Myc Adenovirus particle
    ORF Viral VectorvGMAD000465Norway rat Myc Adenovirus particle
    ORF Viral VectorvGMAAV000056mouse Myc AAV particle


    Target information

    Target IDGM-T36121
    Target NameMYC
    Gene ID4609,17869,24577,694626,403924,100379628,511077,100068097
    Gene Symbol and SynonymsbHLHe39,c-Myc,CMYC,mMyc,MRTL,MYC,Myc2,MYCC,Niard,Nird,RNCMYC,v-myc
    Uniprot AccessionP01106,P09416,B8XIA5,Q28350,P68271,Q2HJ27
    Uniprot Entry NameMYC_HUMAN,MYC_MACMU,MYC_RAT,MYC_FELCA,MYC_CANLF,MYC_BOVIN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseBreast Cancer, Lung Cancer, Lung cancer
    Gene EnsemblENSG00000136997
    Target ClassificationN/A

    The target: MYC, gene name: MYC, also named as MRTLC, bHLHe39, c-Myc, MYC. This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini. [provided by RefSeq, Aug 2017].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.